CervoMed is trading 6.3% lower at $2.07 after its Phase 2b RewinD-LB trial failed to confirm the primary outcome in the full study population.
- Results from the 159-patient study were published October 29.
- Some subgroup and MRI findings were favorable, while broader market weakness added pressure.
- Shares were down from the October 28 close of $2.21; current volume data was unavailable in the sources reviewed.